DANBIO registry: 1600+ pts RA, AxSpA, PsA Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111) Maintenance at 1yr: >80% > withdrawal in original IFX naive, but higher BL DA Do second time switchers do better because of past switch experience? Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz

Yes. But this only accounts for 1/3 of risk to develop clinical RA. We need a better understanding of the other 2/3 so we can propose efficient preventive interventions. #ACR22 @RheumNow https://t.co/RRzlAISFK3

• https://twitter.com/doctorRBC/status/1591825586401710080

Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA. Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity. @RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M

Most important point from the Great Debate on treating pre-RA. Are we really treating to prevent RA or are we simply delaying RA onset? I don't think there is enough data to treat pre-clinical RA with our current arsenal of DMARDs. What would you do? @RheumNow #ACR22

The Great Debate! Should you treat pre-clinical RA? ACPA+ ~40% did not convert to clinical RA RF+/ACPA+ least likely to seroconvert to negative @RheumNow #ACR22 https://t.co/djVPKDdWjz

The Great Debate! Should you treat pre-clinical RA? US erosions in 5th MTPs predict clinical arthritis in +CCP "Pre-RA" patients ~15% of patients will develop RA @RheumNow #ACR22 https://t.co/jS2YMlF4iO

The Great Debate! Should you treat pre-clinical RA? "The more good factors you have, the less likely you will develop RA" - Janet Pope Never smoker, normal BMI, low EtOH, exercise, healthy diet @RheumNow #ACR22 https://t.co/jIMOn8ht6u

#ACR22 The Great Debate: to treat subclinical #Rheumatoidarthritis or not. @Janetbirdope counted hands manually in person. Let's check out the #socialmedia community. What is your definition of sub-clinical RA? @RheumNow

Infections in pre-RA: a cause or a consequence? Rheumatoid arthritis is known to be associated with a higher risk of infections, and this occurs for multiple reasons: immune dysfunction, systemic inflammation, comorbidities, and treatments. https://t.co/N91Goop92l https://t.co/yvnRrsHSCB

• https://bit.ly/3AaHTiP

Dr. Michael Holers on preclinical RA "Individuals who are anti-CCP positive are not clinically well. We just can't see what is going on" @RheumNow #ACR22

The Great Debate! Should you treat pre-clinical RA? First - likelihood of RA? If you have +ACPA or RF in sputum, there is 67% chance of developing clinical RA! @RheumNow #ACR22 https://t.co/K7pUhvbEDR

The great debate Next steps to develop RA prevention Kevin Deane “It’s time to move from disease modifying drugs to disease modifying therapeutic approaches” #ACRdebate #ACR22 @RheumNow https://t.co/3vt58sXlDx

Multiplex peripheral blood in 200+ ILD pts Differences in IL-17 RD-ILD>IPF> IPAF Higher IL-13 strongly asso w/ non-progression of ILD in RD-ILD, IPF & IPAF OR 0.4 Almost surprising considering known profibrotic role of IL-13 🧐 https://t.co/21UMq6w9hI Abs#1109 #ACR22 @Rheumnow https://t.co/7tfk74zH8A

• High Interleukin-13 Level Is Associated with Disease Stability in Interstitial …

There are good reasons why you might want to treat pre-RA. Hard to walk past this promise #ACR22 @RheumNow https://t.co/YHmIl5dsID

USA vs Canada It's kicking off and a super hot topic The Great Debate: To Treat or Not? The Role of DMARDS in Subclinical Rheumatoid Arthritis Holers/Deane (treat 🇺🇸) El Gabalawy/Pope (don't treat 🇨🇦) What more do you want, #ACR22? Bring it on @RheumNow https://t.co/DroQdnSQHf